– USA, CA – Arcus Biosciences, a biotechnology company focused on the discovery and development of innovative cancer immunotherapies, today announced the appointment of Kathryn (“Kate”) Falberg to its Board of Directors.
Ms. Falberg brings extensive financial, strategic and operational experience in the life sciences industry. She most recently served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals PLC. Previously, Ms. Falberg served as Senior Vice President, Finance and Strategy and Chief Financial Officer of Amgen. Ms. Falberg currently serves on the boards of Aimmune Therapeutics, Axovant Sciences, UroGen Pharma and The Trade Desk, and recently served on the Board of Directors of Medivation until its acquisition by Pfizer. Ms. Falberg holds B.A. and M.B.A degrees from UCLA, is a CPA, inactive, and a UCLA Certified Director.
“We are thrilled to have Kate join our Board of Directors,” said Terry Rosen, CEO of Arcus. “As both Chief Financial Officer and board member, Kate has played a significant role in building and establishing the necessary financial and operational infrastructure at several highly successful biopharmaceutical companies. Her experience will be instrumental as Arcus transitions into a clinical-stage immuno-oncology company with the near-term initiation of clinical trials for two of our product candidates, a first-in-class dual adenosine receptor antagonist and a PD-1 antibody. She also shares our passion for bringing innovative cancer drugs to patients.”
Ms. Falberg commented, “I have been extremely impressed by the pace of Arcus’s growth, the breadth of its pipeline and the quality of its team and molecules. I look forward to working with the Arcus Board and senior leadership team to provide financial and strategic guidance as the company’s pipeline matures.”
The appointment of Kate Falberg follows several recent additions to the Arcus senior management team which build upon the outstanding research and drug discovery team and infrastructure that have been established since its inception. Jennifer Jarrett joined the company as Chief Business and Financial Officer. Jennifer most recently served as Chief Financial Officer of Medivation, where she was responsible for finance, accounting, information technology, investor relations, strategy and business development; prior to Medivation, Jennifer spent 20 years in investment banking, most recently at Citigroup, covering biotechnology companies. Joyson Karakunnel, MD, FACP, joined the company as Vice President, Clinical Development, earlier this year. Previously, Joyson oversaw several oncology programs at MedImmune, a member of the AstraZeneca group, where he led some of their key immuno-oncology clinical trials, including those evaluating PD-L1 and CTLA-4 antibodies. In addition, Tim Sullivan, PhD, joined the company as Vice President, Business Development. Prior to joining Arcus, Tim was a Senior Director in the External R&D Innovation (ERDI) group at Pfizer, where he focused on identifying new immuno-oncology opportunities across all therapeutic modalities, as well as managing the global alliances with Servier and Cellectis.
About Arcus Biosciences
Arcus Biosciences is a biotechnology company focused on the discovery and development of innovative cancer immunotherapies. Arcus was founded in 2015 by Terry Rosen and Juan Jaen, the co-founders of Flexus Biosciences, which in February 2015 was acquired by Bristol-Myers Squibb to access Flexus’s IDO inhibitor, which was in preclinical development at the time and is now referred to as BMS-986205. Arcus has several programs targeting important immuno-oncology pathways, including a first-in-class dual adenosine receptor antagonist and a PD-1 antibody, both of which are about to enter phase 1 studies, as well as a first-in-class small molecule inhibitor of CD73 and a TIGIT antibody, which are in IND-enabling studies. Arcus has over 70 employees with extensive expertise in medicinal chemistry, immunology, biochemistry, pharmacology, and structural biology. To date, Arcus has raised $120mm in funding from investors including GV (previously known as Google Ventures), Foresite Capital, The Column Group, Invus LP, Novartis, Celgene, Taiho Ventures, Stanford University, and DROIA, as well as from senior management. The company is based in Hayward, CA.
For more information : http://www.arcusbio.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.